Table 3.

Genomic profiles and clinical information of patients who were enrolled into clinical trial.

IndexGeneAA changeAllele frequency (%)Copy numberTMBDrugs in clinical trialsBest responsePFS (weeks)
Patient 1KRASAmplification144.0RAF inhibitorNE1.9
Patient 2NRASG12D88.84.9RAF inhibitorPD3.0
Patient 3NRASG13D89.22.0RAF inhibitorPD28.1
Patient 4NRASQ61L758.0RAF inhibitorSD15.3
Patient 5NRASQ61K45.83.3RAF inhibitorSD7.3
Patient 6KIT/KDR/PDGFRAAmplification1335.0Multiple receptor tyrosine kinase inhibitorSD12.6
Patient 7MSH6T955fs31.874.0Anti-PD-L1 antibodySD100.4
  • Abbreviation: NE, not evaluable.